[Crossref] [PubMed] Do D, Lee T, Peasah SK, et al
Oncology drugs continue to be a major cost driver, with double-digit spending growth due to expensive new therapies and expanded treatments
doi: 10.3389/fphar.2026.1736380 Received 10 November 2025 Revised 20 January 2026 Accepted 21 January 2026 Published 10 February 2026 Volume 17 - 2026 Edited by Madhusudan Prasad Singh, All India Institute of Medical Sciences Raipur, India Reviewed by Hemasri Velmurugan, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India Prachi Arunima, All India Institute of Medical Sciences Raipur, India Updates Copyright 2026 Wali, Rangraze, Khan, Mufti, El-Tanani and Rizzo
Using Ozempic or Other GLP-1 Agonists for Weight Loss: Considerations and Risks While Ozempic was initially developed to manage Type 2 diabetes, its ability to promote weight loss has made it a popular choice for individuals seeking to shed excess pounds
GLP-1 WEIGHT-LOSS MEDICATIONS LINKED TO IMPROVED CANCER SURVIVAL IN CERTAIN PATIENTS Despite the risks, some older Americans are reportedly abandoning their weight-loss medications for a variety of reasons, from intense side effects to climbing costs
Expanded Approval for Pediatrics With rising rates of diabetes and excess weight in children, the FDA has expanded the use of incretin-based therapies to younger populations
